Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02684006 · ClinicalTrials.gov registry record · Phase 3
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 886
- Enrollment target
NCT02684006 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 886 participants.
The verdict
NCT02684006, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 886 participants
- Enrollment target
Study Summary
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma
Interventions
- DRUG Sunitinib
- DRUG Axitinib (AG-013736)
- DRUG Avelumab (MSB0010718C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 886 participants |
| Start Date | 2016-03-23 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02684006
The ClinicalTrials.gov registry entry for NCT02684006 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 886 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sunitinib is the first listed.
NCT02684006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02684006 about?
NCT02684006 is a clinical study titled "A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)". This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma
What is the current status of trial NCT02684006?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 886 participants. The study started on 2016-03-23. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT02684006?
The interventions under investigation include: Sunitinib (DRUG), Axitinib (AG-013736) (DRUG), Avelumab (MSB0010718C) (DRUG).
Who is sponsoring clinical trial NCT02684006?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.